{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:06:30Z","timestamp":1794650790070,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.eururo.2020.11.013","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T07:42:26Z","timestamp":1607154146000},"page":"343-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":277,"title":["Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA"],"prefix":"10.1016","volume":"79","author":[{"given":"Benedikt","family":"Feuerecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4770-3307","authenticated-orcid":false,"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-9424","authenticated-orcid":false,"given":"Ali","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Pickhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-8260","authenticated-orcid":false,"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"D\u2019Alessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.11.013_bib0005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.11.013_bib0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.11.013_bib0015","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043\/022OL. http:\/\/www.leitlinienprogramm-onkolo-gie.de\/leitlinien\/prostatakarzinom\/."},{"key":"10.1016\/j.eururo.2020.11.013_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2967\/jnumed.119.236414","article-title":"Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ((177)Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0030","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2020.11.013_bib0035","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/imt.14.16","article-title":"Radioimmunotherapy with alpha-particle-emitting radionuclides","volume":"6","author":"Seidl","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.eururo.2020.11.013_bib0045","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.18632\/oncotarget.2986","article-title":"Alpha-Radioimmunotherapy with (213)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma","volume":"6","author":"Teiluf","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2020.11.013_bib0050","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0055","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with (225)actinium and (213)bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.eururo.2020.11.013_bib0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s13187-015-0954-5","article-title":"Analysis of quality of life subjective perception by patients treated for prostate cancer with the EORTC QLQ-C30 questionnaire and QLQ-PR25 module","volume":"32","author":"Dabrowska-Bender","year":"2017","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.eururo.2020.11.013_bib0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2020.11.013_bib0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.119.229229","article-title":"Predictors of overall and disease free survival in metastatic castration-resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand therapy","volume":"61","author":"Sathekge","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0080","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2020.11.013_bib0085","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.18632\/oncotarget.26789","article-title":"(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer","volume":"10","author":"von Eyben","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2020.11.013_bib0090","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2020.11.013_bib0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2014.10.014","article-title":"Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study","volume":"68","author":"Caffo","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.11.013_bib0100","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.7150\/thno.35759","article-title":"Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617","volume":"9","author":"Kessel","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2020.11.013_bib0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1754-4505.1998.tb00914.x","article-title":"Salivary sIgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: an exploratory study","volume":"18","author":"Harrison","year":"1998","journal-title":"Spec Care Dentist"},{"key":"10.1016\/j.eururo.2020.11.013_bib0110","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.18632\/oncotarget.12240","article-title":"Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer","volume":"8","author":"Fendler","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2020.11.013_bib0115","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0120","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0125","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1200\/JCO.2017.35.6_suppl.162","article-title":"A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Karzai","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.11.013_bib0130","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3892\/mco.2015.628","article-title":"Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: a retrospective study","volume":"3","author":"Caubet","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.eururo.2020.11.013_bib0135","first-page":"466","article-title":"Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617","volume":"60","author":"Bruchertseifer","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0140","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"(225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2020.11.013_bib0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","article-title":"(225)Ac-PSMA-617 for therapy of prostate cancer","volume":"50","author":"Kratochwil","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0150","first-page":"77","article-title":"Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?","volume":"60","author":"Langbein","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2020.11.013_bib0155","first-page":"464","article-title":"Radioligand therapy using combination of Ac-225 and Lu-177 labelled PSMA ligands for progressive end-stage metastatic prostate cancer: effective trade-off between response and toxicity","volume":"60","author":"Kulkarni","year":"2019","journal-title":"J Nucl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820308770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820308770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:07:53Z","timestamp":1759583273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283820308770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0302283820308770"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.11.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}